Financhill
Back

Outlook Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
38

OTLK
Outlook Therapeutics

Last Price:
6.06
Seasonality Move:
-9.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Outlook Therapeutics Price Quote

$6.06
+0.02 (+0.17%)
(Updated: November 5, 2024 at 3:04 AM ET)

Outlook Therapeutics Key Stats

Sell
38
Outlook Therapeutics (OTLK) is a Sell

Day range:
$5.95 - $6.24
52-week range:
$4.61 - $12.85
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
12.19
P/B ratio:
0%

Volume:
174.2K
Avg. volume:
255.8K
1-year change:
-29.34%
Market cap:
$142.9M
Revenue:
$0
EPS:
$-10.77

How Much Does Outlook Therapeutics Make?

Data Unavailable

Is Outlook Therapeutics Growing As A Company?

Data Unavailable

Outlook Therapeutics Stock Price Performance

What Is Outlook Therapeutics 52-Week High & Low?

Outlook Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Outlook Therapeutics?

Is Outlook Therapeutics Cash Flow Positive?

  • What Is OTLK Cash Flow From Operations?
    Cash flow from operations (TTM) is -$64.6M
  • What Is Outlook Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $62.9M
  • What Is Outlook Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Outlook Therapeutics Return On Invested Capital

Data Unavailable

Outlook Therapeutics Earnings Date & Stock Price

Outlook Therapeutics Competitors

Outlook Therapeutics Dividend Yield

Outlook Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -43.79%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 39.50
Upside from Last Price: 553.97%

Major Shareholders

  • How many OTLK shares are owned by institutional investors?
    36.7M OTLK shares are owned by institutional investors
  • How many OTLK shares are owned by insiders?
    10.6M OTLK shares are owned by insiders